Day 3 of the 2013 BIO Conference

Session on Obamacare's Impact on Biotech I started off the conference on Wednesday attending a session discussing the Affordable Care Act. The new law brings up some concerns for biotech businesses since the act significantly affects which drugs are reimbursed under health insurance, particularly Medicare and Medicaid. Changes in how drugs are sold and paid for will influence how they are developed and produced. It was an illuminating discussion that I intend to provide further details on in an article later. However, the short version is that there has to be a return for the costly and risky investment required to develop new innovative drugs, otherwise these new treatments won't be developed....Read Full Post
Source: About.com Biotech Biomedical - Category: Biotechnology Source Type: news